News
GSK
39.66
+0.98%
0.39
EUROPE RESEARCH ROUNDUP-Alfen, Boliden, Pennon Group
Alfen, Boliden, Pennon Group revise their ratings and price targets on several European companies. Securities analysts revise ratings and target prices on companies including Adidas, Airbus and Akzo Nobel. A number of analysts raise their ratings on Adidas and Asos, while others cut their targets.
Reuters · 2d ago
BRIEF-GSK Announces Results From Long-Term Data Relating To Shingrix
GSK Announces Results From Long-Term Data Relating To Shingrix. Results from long-term data show 79.7% EFFICACY in 50-plus year old people. No new safety concerns were identified from the data. GSK plc: Results from data relate to shingrix.
Reuters · 2d ago
BRIEF-GSK Announces Additional Eagle-1 Results
GSK Announces Additional Eagle-1 Results. GSK says data show potential for GEPOTIDACIN as a new oral treatment option. The company says the drug has a 92.6% success rate in clinical trials for a new treatment for rheumatology.
Reuters · 2d ago
Health Rounds: RSV infection raises heart risk in unvaccinated adults
Health Rounds: RSV infection raises heart risk in unvaccinated adults raises heart risks. Cardiac events are common among older un vaccinated adults who are hospitalized with respiratory syncytial virus. Heart failure from cancer drugs may be preventable, researchers say. The study looked at the effects of RSV and cancer drugs known as anthracyclines.
Reuters · 2d ago
Weekly Report: what happened at GSK last week (0408-0412)?
Weekly Report · 4d ago
UPDATE 2-AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition
AstraZeneca CEO Pascal Soriot eligible to earn as much as $23.7 million this year. Policy approved with two-third of votes in favour of CEO Soriot's pay package. Over a third of investors revolted against the huge sum. High executive pay in Britain has long been contentious.
Reuters · 04/11 16:53
Pfizer RSV shot meets goals in trial of high-risk adults under age 60
Pfizer RSV shot meets goals in trial of high-risk adults under age 60. Pfizer's respiratory syncytial virus vaccine Abrysvo was well tolerated and generated immune response in higher risk adults under the age of 60. The shot is already approved for older adults but Pfizer plans to seek expanded approval of the vaccine.
Reuters · 04/09 10:45
VIIV HEALTHCARE ANNOUNCES U.S. FDA APPROVAL OF DOVATO (DOLUTEGRAVIR/LAMIVUDINE) FOR ADOLESCENTS LIVING WITH HIV
Reuters · 04/08 12:23
Weekly Report: what happened at GSK last week (0401-0405)?
Weekly Report · 04/08 09:12
EUROPE RESEARCH ROUNDUP-Azelis, Drax Group, Rentokil Initial
Azelis, Drax Group, Rentokil Initial revise ratings and price targets on several European companies. Analysts revise their ratings and target prices on several companies. Azelis, drax group and rentokil initial among those revised on Monday.
Reuters · 04/08 06:39
UPDATE 2-Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts
Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts. Sanofi still faces about 20,000 lawsuits over the discontinued heartburn drug in Delaware state court. The company says it is settling to avoid the expense and distraction of the litigation. The agreement will resolve most of the lawsuits against the French company.
Reuters · 04/03 21:40
EXPLAINER-What to know about bird flu in dairy cows and the risk to humans
Texas officials say a farm worker tested positive for bird flu in dairy cows. The virus has infected cows in Texas, Kansas, New Mexico, Michigan and Idaho. The risk to humans remains low. The U.S. Has a stockpile of bird flu vaccines for humans.
Reuters · 04/03 20:37
UPDATE 2-Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs
President Joe Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs. Biden says prescription drugs cost at least two to three times more in the U.S. Than in other countries. Biden wants to lower prices for 50 drugs and limit drug costs for Americans to $2,000 a year. The pharmaceutical industry defends industry practices.
Reuters · 04/03 17:32
Weekly Report: what happened at GSK last week (0318-0322)?
Weekly Report · 03/25 09:12
UK Stocks-Factors to watch on March 21
Britain's FTSE 100 index is seen opening higher on Thursday. Futures for the index are up 0.8%. Barclays is preparing to axe hundreds of jobs across its investment bank. EasyJet in talks with EU about taking over slots at Milan's Linate airport.
Reuters · 03/21 04:54
GSK to cap out-of-pocket inhaler costs in US
GSK to cap out-of-pocket costs at $35 per month for all its inhaled asthma and chronic lung disease medicines for eligible patients in the United States. British pharmaceutical giant follows similar moves by two of its rivals in the US. GSK to cap costs for inhaler costs in U.S.
Reuters · 03/20 20:50
Pfizer offloads $3.9 bln stake in Sensodyne-maker Haleon
Pfizer offloads $3.9 bln stake in Sensodyne-maker Haleon. Pfizer previously held a 32% stake, followed by second-largest shareholder GSK. Haleon said it would also repurchase 315 million pounds worth of shares from Pfizer.
Reuters · 03/19 08:19
UPDATE 2-AstraZeneca follows rival Boehringer in capping out-of-pocket costs for inhalers
AstraZeneca follows rival Boehringer in capping out-of-pocket costs for inhalers at $35 per month in the U.S. High drug prices in the United States have been the subject of growing political scrutiny. UK-based AstraZeneca's cap will apply to its respiratory products portfolio.
Reuters · 03/18 11:38
Weekly Report: what happened at GSK last week (0311-0315)?
Weekly Report · 03/18 09:12
UPDATE 1-Pfizer to cut stake in Sensodyne toothpaste-maker Haleon to 24%
Pfizer to cut stake in Sensodyne toothpaste-maker Haleon to about 24%. Pfizer currently holds a 32% stake in the company. Haleon makes household brands such as Sensodyn toothpaste and Advil painkillers. The company was spun out of British drugmaker GSK in July 2022.
Reuters · 03/18 07:15
More
Webull provides a variety of real-time GSK stock news. You can receive the latest news about GSK PLC through multiple platforms. This information may help you make smarter investment decisions.
About GSK
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.